Afya Limited

Afya Limited (AFYA) Stock Analysis

$14.590

+0.286 (+1.96%)At close

Loading chart…
High
14.730
Open
14.380
VWAP
14.53
Vol
117.92K
Mkt Cap
1.53B
Low
14.270
Amount
1.71M
EV/EBITDA, TTM
2.01

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.

AI analysis of Afya Limited (AFYA)

buy

Afya Ltd is a good buy right now due to its strong revenue growth of 8% in the latest earnings report, reaching BRL 1.013 billion, and a low forward P/E ratio of 7.13, indicating potential undervaluation. However, the main risk is the significant insider selling, which has increased by 1215.03% over the last month, suggesting potential concerns about the company's future performance.

Valuation Metrics

The current forward P/E ratio for Afya Limited (AFYA) is 7.13, compared to its 5-year average forward P/E of 11.30.

Forward P/E

Undervalued
5Y Average P/E
11.30
Current P/E
7.13
Overvalued
14.43
Undervalued
8.18

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
6.65
Current EV/EBITDA
2.01
Overvalued
9.02
Undervalued
4.28

Forward P/S

Strongly Undervalued
5Y Average P/S
2.20
Current P/S
0.30
Overvalued
3.15
Undervalued
1.25

Alphio AI Price Scenarios for AFYA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AFYA

$28.55

Scenario price

B

Base

Base · 50%AFYA

$24.23

Scenario price

B

Bear

Bear · 25%AFYA

$20.66

Scenario price

Whales holding AFYA

S

SoftBank Group Corp.

+ HoldingAFYA

-39.93%

3M Return

Events Timeline

2026-08-24 (ET)

10:00:00

Afya and Yduqs Discuss Potential Business Combination

2025-11-12 (ET)

18:14:48

Afya announces Q3 adjusted EBITDA of R$398.9M, a 14.6% increase year-over-year

2025-11-07 (ET)

08:54:49

Afya Reveals Expansion of Medical Seats at ITPAC Porto Nacional

2025-08-13 (ET)

18:22:29

Afya still sees 2025 revenue R$3.67B-R$3.77B

18:21:04

Afya reports Q2 EPS R$2.27 vs. R$2.29 last year

News

AFYA FAQ — answered by Alphio AI

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform. It operates in the Academic & Educational Services sector.

Afya Ltd is a good buy right now due to its strong revenue growth of 8% in the latest earnings report, reaching BRL 1.013 billion, and a low forward P/E ratio of 7.13, indicating potential undervaluation. However, the main risk is the significant insider selling, which has increased by 1215.03% over the last month, suggesting potential concerns about the company's future performance.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始